Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

Science

Volumn 278, Issue 5335, 1997, Pages 117-120

  Tamura, Yasuaki ^a   Peng, Ping ^a   Liu, Kang ^a   Daou, Maria ^a   Srivastava, Pramod K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COLON CARCINOMA; DRUG EFFECT; FIBROSARCOMA; LUNG CARCINOMA; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; IMMUNIZATION; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

ANIMALIA;

EID: 0030820099     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.278.5335.117     Document Type: Article

References (36)

1. P. K. Srivastava, Adv. Cancer Res. 62, 153 (1993).
2. Z. Li and P. K. Srivastava, EMBO J. 12, 3143 (1993).
3. H. Udono and P. K. Srivastava, J. Exp. Med. 178, 1391 (1993).
4. A. Heikema, E. Agsteribbe, J. Wilschut, A. Huckriede, Immunol. Lett. 57, 69 (1997).
5. E. Roman and C. Moreno, Immunology 88, 487 (1996).
6. N. E. Blachere et al., J. Exp. Med., in press.
7. P. K. Srivastava and M. R. Das, Int. J. Cancer 33, 417 (1984); P. K. Srivastava et al., Proc. Natl. Acad. Sci. U.S.A. 83, 3407 (1986); M. A. Palladino, P. K. Srivastava, H. F. Oettgen, A. B. DeLeo, Cancer Res. 47, 5074 (1987); A. M. Feldweg and P. K. Srivastava, Int. J. Cancer 63, 310 (1995).
8. P. K. Srivastava and M. R. Das, Int. J. Cancer 33, 417 (1984); P. K. Srivastava et al., Proc. Natl. Acad. Sci. U.S.A. 83, 3407 (1986); M. A. Palladino, P. K. Srivastava, H. F. Oettgen, A. B. DeLeo, Cancer Res. 47, 5074 (1987); A. M. Feldweg and P. K. Srivastava, Int. J. Cancer 63, 310 (1995).
9. P. K. Srivastava and M. R. Das, Int. J. Cancer 33, 417 (1984); P. K. Srivastava et al., Proc. Natl. Acad. Sci. U.S.A. 83, 3407 (1986); M. A. Palladino, P. K. Srivastava, H. F. Oettgen, A. B. DeLeo, Cancer Res. 47, 5074 (1987); A. M. Feldweg and P. K. Srivastava, Int. J. Cancer 63, 310 (1995).
10. P. K. Srivastava and M. R. Das, Int. J. Cancer 33, 417 (1984); P. K. Srivastava et al., Proc. Natl. Acad. Sci. U.S.A. 83, 3407 (1986); M. A. Palladino, P. K. Srivastava, H. F. Oettgen, A. B. DeLeo, Cancer Res. 47, 5074 (1987); A. M. Feldweg and P. K. Srivastava, Int. J. Cancer 63, 310 (1995).
11. H. Udono, D. Levey, P. K. Srivastava, Proc. Natl. Acad. Sci. U.S.A. 91, 3077 (1994).
12. P. Peng, A. Menoret, P. K. Srivastava, J. Immunol. Methods 204, 13 (1997).
13. N. E. Blachere et al., J. Immunother. 14, 351 (1993).
14. R. Suto and P. K. Srivastava, Science 269, 1585 (1995).
15. T. J. F. Nieland et al., Proc. Natl. Acad. Sci. U.S.A. 93, 6135 (1996).
16. D. Arnold, S. Faath, H.-G. Rammensee, H. Schild, J. Exp. Med. 182, 885 (1995).
17. K. Sugiura and C. C. Stock, Cancer Res. 15, 38 (1955).
18. Y. Tamura and P. K. Srivastava, unpublished data.
19. O. Mandelboim et al., Nat. Med. 11, 1179 (1995).
20. M. Daou, R. Suto, P. K. Srivastava, in C.R.I. Cancer Vaccines, Cancer Research Institute (CRI), New York, 7 to 9 October (CRI, New York, 1996).
21. M. J. Skeen, T. M. Shinnick, M. A. Miller, H. K. Ziegler, J. Immunol. 156, 1196 (1996).
22. S. Janetzki, D. Polla, V. Roseanhauer, H. Lochs, P. K. Srivastava, in preparation.
23. R. Y. Chandawarkar, M. Wagh, P. K. Srivastava, unpublished data.
24. A. Globerson and M. Feldman, J. Natl. Cancer Inst. 32, 1229 (1964); M. A. Basombrio, Cancer Res. 30, 2458 (1970).
25. A. Globerson and M. Feldman, J. Natl. Cancer Inst. 32, 1229 (1964); M. A. Basombrio, Cancer Res. 30, 2458 (1970).
26. P. K. Srivastava, Semin. Immunol. 8, 295 (1996); _, H. Udono, N. E. Blachere, Z. Li, Immunogenetics 39, 93 (1994).
27. P. K. Srivastava, Semin. Immunol. 8, 295 (1996); _, H. Udono, N. E. Blachere, Z. Li, Immunogenetics 39, 93 (1994).
28. T. Boon and P. van der Bruggen, J. Exp. Med. 183, 725 (1996).
29. D. M. Pardoll, Nature 369, 357 (1994).
30. L. Ramarathinam et al., J. Immunol. 155, 5323 (1995); A. Y. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9730 (1996); D. E. Speiser et al., J. Exp. Med. 186, 645 (1997).
31. L. Ramarathinam et al., J. Immunol. 155, 5323 (1995); A. Y. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9730 (1996); D. E. Speiser et al., J. Exp. Med. 186, 645 (1997).
32. L. Ramarathinam et al., J. Immunol. 155, 5323 (1995); A. Y. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9730 (1996); D. E. Speiser et al., J. Exp. Med. 186, 645 (1997).
33. All studies involving mice were carried out under protocols approved by the Institutional Animal Care and Use Committee of Fordham University.
34. Antibodies against GP96 (9G10.F8.2) and HSP70 (BRM22) were obtained from NeoMarkers (Fremont, CA).
35. + T cells by intraperitoneal (ip) injection of 250 μl of 1:8 diluted GK1.5 ascites or YTS-169.4 ascites, respectively. Injections were continued biweekly. NK cells were depleted by ip injection of 200 μg of purified monoclonal antibody NK1.1 every week. Mice in the control group were injected with 200 μg of rat or mouse Ig once per week. The efficiency of depletion was confirmed by flow cytometry, and the specific depletion was 90 to 100%.
36. We thank S. Porcino for preparing the figures. Supported by NIH grants CA44786 and CA64394 and through an agreement with Antigenics (New York).